8-[9-ethyl-2-(5-fluoro-1H-indol-4-yl)-6-morpholin-4-yl-9H-purin-8-ylmethyl]-2,8-diazaspiro[4.5]decan-1-one | 1148002-94-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 8-[9-ethyl-2-(5-fluoro-1H-indol-4-yl)-6-morpholin-4-yl-9H-purin-8-ylmethyl]-2,8-diazaspiro[4.5]decan-1-one
• 英文别名: 8-[[9-ethyl-2-(5-fluoro-1H-indol-4-yl)-6-morpholin-4-ylpurin-8-yl]methyl]-2,8-diazaspiro[4.5]decan-1-one
• CAS: 1148002-94-1
• 化学式: C₂₈H₃₃FN₈O₂
• 分子量: 532.621
• InChiKey: XWEMNQQJZWDLBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• [EN] PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PURINE UTILES COMME INHIBITEURS DE PI3 KINASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009053716A1

  公开（公告）日：2009-04-30

  This invention provides a compound which is a purine of formula (Ia) or (Ib): and the pharmaceutically acceptable salts thereof that are inhibitors of PI3K and a selective for the p110δ isoform, which is a class Ia PI3 kinase, over other class Ia PI3 kinases and over class Ib kinases. The compounds may be used to treat diseases and disorders arisi from abnormal cell growth, function or behaviour associated with PI3 kinase such as cance immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

  这项发明提供了一种化合物，其为式(Ia)或(Ib)的嘌呤类化合物：及其药学上可接受的盐，这些化合物是PI3K的抑制剂，并且对p110δ同工型具有选择性，p110δ是Ia类PI3激酶，优于其他Ia类PI3激酶和Ib类激酶。这些化合物可用于治疗由于与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和紊乱，如癌症、免疫紊乱、心血管疾病、病毒感染、炎症、代谢/内分泌功能紊乱和神经系统疾病。
• PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS
  申请人：Goldsmith Paul

  公开号：US20110230464A1

  公开（公告）日：2011-09-22

  This invention provides a compound which is a purine of formula (Ia) or (Ib): and the pharmaceutically acceptable salts thereof that are inhibitors of PI3K and a selective for the p110δ isoform, which is a class Ia PI3 kinase, over other class Ia PI3 kinases and over class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

  本发明提供了一种化合物，即式(Ia)或(Ib)的嘌呤化合物及其药学上可接受的盐，它们是PI3K的抑制剂，且对p110δ亚型具有选择性，该亚型属于Ia类PI3激酶，相对于其他Ia类PI3激酶和Ib类激酶具有优异的选择性。这些化合物可用于治疗由于PI3激酶异常细胞生长、功能或行为引起的疾病和障碍，如癌症、免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌功能障碍和神经障碍。
• PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2215090B1

  公开（公告）日：2015-03-04
• PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS
  申请人：The U.S.A. As Represented By The Secretary, Department Of Health And Human Services

  公开号：EP2365810A2

  公开（公告）日：2011-09-21
• [EN] PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS<br/>[FR] MÉDICAMENTS À CIBLAGE PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA DANS LE TRAITEMENT DES TROUBLES DU SNC
  申请人：US HEALTH

  公开号：WO2010065923A2

  公开（公告）日：2010-06-10

  Methods for treating CNS disorders such as schizophrenia, psychosis and cognitive disorders using specific inhibitors of phosphatidylinositol-3-kinase p110 delta (PIK3CD) expression and/or activity are described. Methods of determining risk of CNS disorders and methods of determining treatment response are also described. An integrative systems biology approach to identify a signaling mechanism and genetic network associated with schizophrenia and with schizophrenia-associated risk variation in ErbB4. A risk pathway associated with ErbB4 genetic variation involving increased expression of a PI3K-linked ErbB4 receptor CYT-1 and a specific PI3K enzyme, PIK3CD has been identified.